

## **Doseology Announces Officer Changes**

Kelowna, British Columbia, June 30, 2023, **Doseology Sciences Inc.** (<u>CSE: MOOD</u>) (<u>OTCQB: DOSEF</u>) (<u>FSE: VU7</u>) (the "Company"), a life sciences company focused on mental health and wellness, is pleased to announce the appointment of Shawn Balaghi the Interim CEO and Interim CFO of the Company, effective immediately.

Shawn brings over 20 years of experience in the capital markets industry globally, holding key roles in finance, corporate development, and strategic planning. Previously, he has served as the CEO and CFO, and Director for several publicly listed companies and has worked closely with some of the largest independent auditing firms in Canada and the US. Shawn has raised over \$300 Million in funding for several start-ups and has led them to public listings in Canada, the US, and Germany. Shawn has been the President, Director & Co-Founder of RED Bioscience since July 2020, and successfully ran trials at the University of British Columbia on an all-natural formulation preventing and deactivating several variations of the Covid Virus.

The Company also announces that Pratik Patel has resigned as the CFO, Interim CEO and a director of the Company and wishes him well in his future endeavors.

On Behalf of the Board of Directors

Shawn Balaghi Interim CEO Doseology Sciences Inc.

## About Doseology Sciences (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU7)

Doseology Sciences Inc. is building a progressive brand focused on mental health and wellness through innovative nutraceutical products. Doseology aims to make a meaningful impact on the mental health pandemic by utilizing and developing functional fungi. The Doseology functional mushroom line is available on <u>doseology.com</u>.

## For Further Information Contact:

Investor Relations: <a href="mailto:investor@doseology.com">investor@doseology.com</a> General Inquiries: <a href="mailto:hello@doseology.com">hello@doseology.com</a>

Telephone: 236-349-0064 Website: <u>doseology.com</u>

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.